Navigation Links
ClearTrial to Chair Session at DIA 45th Annual Meeting on "Effective Operational Planning for Adaptive Clinical Trials"
Date:6/2/2009

*Improving budgeting and forecasting accuracy
*IT considerations, including interactive voice response, electronic data capture, and upfront database design
*Impact of adaptive trial designs on drug supply

Blake-Michaels brings more than 20 years of clinical operations experience to the DIA session, with extensive experience in the strategic planning and execution of clinical development programs across a wide variety of therapeutic areas. Before joining ClearTrial, she worked for pharmaceutical companies such as Abbott Labs, Fujisawa, TAP, Hospira, and Ovation, as well as one of the largest clinical research organizations. Blake-Michaels has authored over 50 clinical study protocols that included adaptive studies, several investigator brochures and FDA briefing books, and multiple NDA summary documents. As an independent clinical research consultant, she prepared clients for FDA Advisory Committee meetings and post-acquisition portfolio reviews, and planned and managed numerous studies, including a REMS-required patient registry.

About ClearTrial®
ClearTrial® is a leading provider of clinical trial software for clinical operations planning, budgeting, and outsourcing. ClearTrial's award-winning software helps pharmaceutical, biotechnology, medical device companies, and CROs expedite the clinical development process without sacrificing quality of results. The company's software products support clinical operations, resource planning, and outsourcing departments with a single solution that promotes speed and consistency, while maintaining flexibility to handle different study requirements. For more information please visit http://www.cleartrial.com.

ClearTrial® and the ClearTrial logo are registered trademarks owned by ClearTrial, LLC, which may be registered in certain jurisdictions. Any other company or product names mentio
'/>"/>

Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved

Page: 1 2 3

Related biology technology :

1. ClearTrial Names Software Industry Veteran Michael Bruns as Chief Operating Officer
2. ClearTrial Launches Version 2.7 of its Clinical Trial Operations Planning Software Featuring Advanced Portfolio Planning Capability
3. ClearTrial Selected to Lead Industry Panel on Managing Clinical Trial Cash Flow and Accruals at CBI Conference
4. InspireMD Announce the Completion of Enrollment for the MAGICAL Trial (MGuard(TM) in Acute Myocardial Infarction) at EuroPCR 09. Results Will be Presented May 21st by Dr. Dariusz Dudek at the InspireMD Cocktail Reception Debate Chaired by Prof. Martin Le
5. Matt Bars, a Global Expert in Smoking Cessation, Joins Next Safety as Chairman
6. Vasogen Appoints Dr. Eldon Smith Chairman
7. Keryx Biopharmaceuticals, Inc. Announces Michael P. Tarnok as Interim Chairman and Chief Executive Officer
8. Spherix Incorporated Announces the Death of A. Paul Cox, Jr., Chairman of the Board
9. Joseph Loscalzo, M.D., PhD. to Join N30 Pharma Board and Chair Scientific Advisory Board
10. Peregrine Pharmaceuticals Mourns Loss of Chairman Thomas A. Waltz
11. Intellect Neurosciences, Inc. Issues Letter to Shareholders From Its Chairman and CEO
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)... the right people at the table for significant business ... achieving clinical and operational goals. The 22 nd ... 2014, in San Diego , featured ... discussing how partnerships have positively impacted their objectives. ... Officer of Cape Regional Medical Center located in ...
(Date:7/23/2014)... , July 23, 2014 ... portfolio company of Trendlines Agtech , announced ... Israel,s leading agricultural thermoplastics ... Valentis,s technology combines nanocrystalline cellulose (NCC), ... waste, with additional nanoparticles to produce highly improved ...
(Date:7/23/2014)... -- regulated information -- UCB today announced an important ... positive topline results from the latest Phase 3 ... to evaluate the efficacy and safety of ... compared to placebo, as adjunctive treatment in adult ... controlled despite treatment with one or two concomitant ...
(Date:7/23/2014)... July 23, 2014  Sofinnova Ventures, a ... the closing of Sofinnova Venture Partners IX, L.P. at ... of the initial fund target of $425 million. ... biotechnology companies. Consistent with recent funds, SVP IX will ... clinical programs, along with select investments in earlier stage ...
Breaking Biology Technology:MSC and Cape Regional Medical Center Partner to Improve Cost, Quality and Outcomes 2Valentis Nanotech Signs MOU to Integrate Technology in Thermoplastics Production 2Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 2Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 3Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 4Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 5Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 6Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 7Sofinnova Raises $500 Million Biotech Venture Fund 2
... - YM BioSciences Inc. (NYSE Alternext US:YMI, ... develops and commercializes differentiated products for patients ... clearance from Canadian regulatory authorities to initiate ... nimotuzumab, its EGFR-targeting antibody, in combination with ...
... Start of Q4 2008 , - Evaluation of strategic alternatives ... RoleSAN DIEGO, Jan. 5 ADVENTRX Pharmaceuticals, Inc. (NYSE Alternext ... reduction-in-force in an effort to extend its remaining cash and ... a reduction implemented in October 2008. In all, the ...
... Jan. 5 LightLab Imaging Inc. today,announced ... past year that are,the culmination of sustained ... These advances significantly increase the Company,s leadership,position ... OCT is a new,high-resolution, high-speed imaging ...
Cached Biology Technology:YM BIOSCIENCES RECEIVES CLEARANCE TO INITIATE RANDOMIZED DOUBLE-BLIND CLINICAL TRIALS OF NIMOTUZUMAB IN LUNG CANCER AND BRAIN METASTASES FROM LUNG CANCER 2YM BIOSCIENCES RECEIVES CLEARANCE TO INITIATE RANDOMIZED DOUBLE-BLIND CLINICAL TRIALS OF NIMOTUZUMAB IN LUNG CANCER AND BRAIN METASTASES FROM LUNG CANCER 3YM BIOSCIENCES RECEIVES CLEARANCE TO INITIATE RANDOMIZED DOUBLE-BLIND CLINICAL TRIALS OF NIMOTUZUMAB IN LUNG CANCER AND BRAIN METASTASES FROM LUNG CANCER 4YM BIOSCIENCES RECEIVES CLEARANCE TO INITIATE RANDOMIZED DOUBLE-BLIND CLINICAL TRIALS OF NIMOTUZUMAB IN LUNG CANCER AND BRAIN METASTASES FROM LUNG CANCER 5YM BIOSCIENCES RECEIVES CLEARANCE TO INITIATE RANDOMIZED DOUBLE-BLIND CLINICAL TRIALS OF NIMOTUZUMAB IN LUNG CANCER AND BRAIN METASTASES FROM LUNG CANCER 6YM BIOSCIENCES RECEIVES CLEARANCE TO INITIATE RANDOMIZED DOUBLE-BLIND CLINICAL TRIALS OF NIMOTUZUMAB IN LUNG CANCER AND BRAIN METASTASES FROM LUNG CANCER 7ADVENTRX Announces Further Cost-Cutting Measures 2ADVENTRX Announces Further Cost-Cutting Measures 3ADVENTRX Announces Further Cost-Cutting Measures 4ADVENTRX Announces Further Cost-Cutting Measures 5LightLab Imaging Leads Global Advancement of Intracoronary Imaging 2LightLab Imaging Leads Global Advancement of Intracoronary Imaging 3
(Date:7/23/2014)... drought that has the entire country in its grip is ... also be responsible for the proliferation of a heat-loving amoeba ... and hot springs, which the drought has made warmer than ... of an infection caused by this parasite after swimming in ... nose of an individual and travels to the brain. Nose ...
(Date:7/23/2014)... The Worldwide Innovative Networking in personalized cancer medicine, ... Cancer Center at Thomas Jefferson University will ... only member of this prestigious group in the Tri-State ... delivery of innovative personalized medicine to the patient by ... advocacy. , "Our participation in the WIN consortium means ...
(Date:7/23/2014)... play an increasingly important role in carbon and nutrient ... expand, according to research published this week in the ... , University of British Columbia researchers plumbed the depth ... chart how microbial community metabolism changes as oxygen minimum ... picture of how SUP05 a bacterial group related ...
Breaking Biology News(10 mins):Diseases of another kind 2New partnership brings more personalized cancer treatment to Philadelphia 2Research charts the ecological impact of microbial respiration in the oxygen-starved ocean 2
... New Rochelle, NY, September 9, 2010A subset of ... associated with more illness and greater allergic hypersensitivity, ... Blood, and Lung Institute,s Severe Asthma Research Program ... Pediatric Allergy, Immunology, and Pulmonology , a ...
... The National Institutes of Health is launching two major ... curtail the nation,s childhood obesity epidemic. One will ... and the other will examine community efforts to reduce ... public health concern. If we don,t curb this widespread ...
... USDA Agriculture and Food Research Initiative (AFRI) grant will help ... gene system of sorghum will lead to enhanced bioenergy production ... we already know about and tailoring them to bioenergy uses ... professor of crop sciences and member of the Energy Biosciences ...
Cached Biology News:Research and insights on severe asthma in children 2NIH-funded studies aim to prevent, treat childhood obesity 2NIH-funded studies aim to prevent, treat childhood obesity 3U of I receives $1 million USDA grant to study Glossy15 in sorghum 2
Bovine Coronary Artery Smooth Muscle Cells (BCASMC) (>500,000 cells)...
RECK (F-20)...
The improved design and new mechanical solutions of Finnpipette Focus Multichannel Plus improves accuracy and precision.In these low volume multichannel pipettes, the super blow-out function ensures ...
NAK/TBK1 (CT) Affinity Purified Polyclonal Antibody...
Biology Products: